GSK strikes $2.2bn deal to resolve legal cases in US over heartburn treatment Zantac

GSK had argued there was no evidence to suggest an increased cancer risk from Zantac and has not admitted any liability in the settlements. Photograph: Drew Angerer/Getty Images

The British drugmaker GSK has struck an agreement to make a payment of up to $2.2bn (£1.7bn) to resolve litigation brought in the US over its heartburn treatment Zantac.

The company said it had struck agreements with 10 plaintiff law firms who represent about 93%, roughly 80,000, of the US state court product liability cases pending against it.